Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Methylphenidate to Treat Methamphetamine Dependence (MPH)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2014 by University of California, Los Angeles.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Walter Ling, University of California, Los Angeles Identifier:
First received: January 6, 2010
Last updated: May 19, 2014
Last verified: May 2014
This 4-year study will investigate the effectiveness of methylphenidate for initiating and sustaining abstinence in methamphetamine dependent individuals. Approximately 90 participants seeking treatment for methamphetamine dependence will be enrolled in the study for an initial 2 weeks to establish clinic compliance. During this compliance phase, participants will receive incentives for clinic attendance. After meeting clinic attendance requirements, participants will be randomized to placebo (n = 45) or active study medication (n = 45) conditions, and given 18mg/daily of study drug or placebo for one week, followed by 36mg/daily study drug/placebo for a second week. Finally, participants will be stabilized on 54mg/daily study drug/placebo for the remainder of the study. Placebo participants will be given placebo medications prepared to appear identical to the active medication. In addition, after randomization, all participants will receive motivational incentives for methamphetamine-negative urine tests and begin weekly cognitive behavioral therapy (CBT) provided for the duration of the study.

Condition Intervention Phase
Methamphetamine Dependence
Drug: methylphenidate
Drug: Methylphenidate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sustained-Release Methylphenidate for Management of Methamphetamine Dependence

Resource links provided by NLM:

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • percentage of methamphetamine-negative urine samples compared across two conditions [ Time Frame: 14-week study duration ]

Secondary Outcome Measures:
  • Retention: number of days retained in treatment from randomization to the last scheduled clinic visit [ Time Frame: 14 week study duration ]

Estimated Enrollment: 90
Study Start Date: October 2010
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: active medication (methylphenidate)
Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
Drug: methylphenidate
18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
Other Name: Concerta
Placebo Comparator: Placebo
Condition randomly assigned to receive placebo, provided to appear identical to active medication
Drug: Methylphenidate
18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
Other Name: Placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be seeking treatment for their MA use disorder;
  2. Be between 18-55 years of age;
  3. Meet DSM-IV-TR criteria for MA dependence as assessed by the Mini International Neuropsychological Interview (MINI);

Exclusion Criteria:

  1. Have any history or evidence suggestive of seizures or brain injury;
  2. Have any known hypersensitivity or previous medically adverse reaction to methylphenidate;
  3. Have a neurological or psychiatric disorder, such as psychosis, bipolar illness, motor tics, Tourette's syndrome, or major depression; organic brain disease or dementia; marked anxiety, tension and agitation; or any psychiatric disorder that would require ongoing treatment or that would make study compliance difficult;
  4. Have evidence of clinically significant heart disease or hypertension as determined by medical history or physical examination, including pre-existing heart failure, recent myocardial infarction, ventricular arrhythmia, cardiomyopathy, serious heart rhythm abnormalities, and coronary artery disease.
  5. Have a family history in first-degree relatives of early cardiovascular morbidity or mortality, as determined by medical history;
  6. Have evidence of an untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease (other than HIV);
  7. Have clinically significant abnormal vital signs;
  8. Have clinically significant abnormal hematology or chemistry laboratory tests [e.g. liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase), kidney function tests (creatinine and BUN)];
  9. Have a baseline ECG that demonstrates clinically significant abnormalities;
  10. Have known preexisting severe gastrointestinal narrowing,
  11. Be pregnant or nursing. Females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or use a reliable form of contraception including hormonal (oral, Depo-Provera or Nuva-ring), intra-uterine devise, sterilization or double barrier method (simultaneous use of two barrier methods such as condom, diaphragm, spermicide);
  12. A history of glaucoma;
  13. Use of some medications such as Clonidine, coumarin anticoagulants, anticonvulsants (Phenobarbital, phenytoin, primidone), vasopressor agents, and some antidepressants (tricyclics and selective serotonin reuptake inhibitors),. Also, current use of an MAO inhibitor, or use within 14 days of enrollment;
  14. Have any other medical condition that would, in the opinion of the study physician, make participation difficult or unsafe.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01044238

United States, California
UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center
Los Angeles, California, United States, 90025
Sponsors and Collaborators
University of California, Los Angeles
Principal Investigator: Walter Ling, M.D. UCLA Integrated Substance Abuse Programs
Study Director: Maureen Hillhouse, Ph.D. UCLA Integrated Substance Abuse Programs
  More Information

Responsible Party: Walter Ling, PI, University of California, Los Angeles Identifier: NCT01044238     History of Changes
Other Study ID Numbers: 1R01DA025084 ( US NIH Grant/Contract Award Number )
Study First Received: January 6, 2010
Last Updated: May 19, 2014

Keywords provided by University of California, Los Angeles:
clinical trial
random assignment
double blind
reduction in methamphetamine use

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors processed this record on April 21, 2017